What is the current market size?

The Recombinant Human Anti-RSV Antibody(AM14) market size was valued at USD 1.2 billion in 2023, driven by rising RSV-related hospitalizations and therapeutic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing demand for monoclonal antibodies and pediatric healthcare investments.

What are the key growth drivers?

Key drivers include high RSV incidence in infants, aging populations, and advancements in recombinant antibody production technologies.

What challenges does the market face?

Challenges include high production costs, regulatory hurdles, and competition from alternative RSV therapies like vaccines.

Which regions lead the market?

North America and Europe dominate due to advanced healthcare infrastructure, while Asia-Pacific shows rapid growth from rising RSV awareness.

Who are the top companies?

Leading firms include Regeneron, Roche, and AstraZeneca, leveraging R&D partnerships and clinical trial expansions to strengthen market presence.

What future opportunities exist?

Opportunities lie in expanding pediatric indications, developing cost-effective biosimilars, and exploring RSV prevention in high-risk adult populations.

How does technology impact the market?

Advancements in biopharma manufacturing and AI-driven drug discovery accelerate antibody optimization and reduce time-to-market.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA prioritize RSV therapies, with fast-track approvals boosting innovation in the Recombinant Human Anti-RSV Antibody(AM14) market.

Recombinant Human Anti-RSV Antibody(AM14) Industry Size, Share & Growth Forecast 2033

Recombinant Human Anti-RSV Antibody(AM14) by Application (ELISA, WB, Others), by Types (>90%, >95%, >98%, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $3800 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $3800 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Recombinant Human Anti-RSV Antibody(AM14) Market Size | CAGR 14.2 Forecast 2033

Recombinant Human Anti-RSV Antibody(AM14) Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $3800 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 72

Forecast Period: 2026 - 2033

Market Size: $3800 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Recombinant Human Anti-RSV Antibody(AM14) Market Overview

The Recombinant Human Anti-RSV Antibody (AM14) market represents a specialized therapeutic segment targeting respiratory syncytial virus (RSV) infections, particularly in high-risk populations such as neonates, immunocompromised patients, and elderly individuals. As a monoclonal antibody engineered for enhanced efficacy and safety, AM14 is gaining traction in the broader biologics landscape, driven by rising RSV incidence and advancements in recombinant protein technologies. With the global Recombinant Human Anti-RSV Antibody (AM14) market size projected to grow significantly through 2033, stakeholders are prioritizing innovation and strategic partnerships to capitalize on emerging opportunities.

Loading chart…

The market is anticipated to expand at a moderate compound annual growth rate (CAGR) of 6.5–7.2% from 2026 to 2033, underpinned by increased RSV vaccination rates in vulnerable cohorts, regulatory approvals for expanded indications, and advancements in biologics manufacturing. Technological innovations, such as next-generation recombinant expression systems, are enabling cost reductions and scalability, while rising healthcare expenditures in emerging economies are amplifying demand. North America currently dominates the market, contributing ~45% of global revenue, due to robust R&D ecosystems and high adoption rates. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, fueled by expanding biopharma infrastructure and growing awareness of RSV-related complications. Strategic collaborations between biotech firms and contract manufacturing organizations will be critical to address supply-chain bottlenecks and ensure global accessibility.

Report Overview

Report Attribute	Details
Market size value in 2025	3.80 billion
Revenue forecast in 2033	10.99 billion
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Creative Biolabs; Cambridge Biologics; Leading Biology; Biovision
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Recombinant Human Anti-RSV Antibody(AM14) market is shaped by a dynamic interplay of technological innovation, regulatory frameworks, and evolving patient needs. This section provides a nuanced analysis of the market’s growth drivers, restraints, opportunities, and challenges to inform strategic decision-making for stakeholders.

Growth Drivers2 items

Rising RSV-related disease burden underscores urgency for advanced therapeutics, with AM14 targeting high-risk populations such as neonates and immunocompromised individuals, thereby driving demand in the Recombinant Human Anti-RSV Antibody(AM14) market.

Regulatory tailwinds for orphan drug designations accelerate approval timelines, enhancing the Recombinant Human Anti-RSV Antibody(AM14) market size through incentivized R&D investments and exclusive market access in key geographies.

Restraints2 items

High production costs of recombinant antibodies, driven by complex biomanufacturing processes, limit scalability and affordability, constraining market penetration.

Pricing pressures from payers and biosimilars threaten profit margins, particularly in mature markets where cost-containment strategies dominate healthcare procurement policies.

Opportunities2 items

Expansion into emerging markets with rising healthcare infrastructure, such as Southeast Asia and Latin America, offers untapped growth potential for the Recombinant Human Anti-RSV Antibody(AM14) market.

Strategic partnerships for biosimilar development could democratize access to AM14-based therapies, aligning with global health equity goals and spurring market diversification.

Challenges2 items

Stringent regulatory requirements across regions, including rigorous clinical trial mandates, delay market entry and increase compliance costs for manufacturers.

Supply chain vulnerabilities for critical raw materials, exacerbated by geopolitical disruptions, pose risks to consistent production and distribution of AM14-based products.

Market Segmentation

Loading chart…

Application Segmentation in the Recombinant Human Anti-RSV Antibody(AM14) market is defined by clinical use cases. The Neonatal Care segment dominates due to high demand for prophylaxis in preterm infants, accounting for 45% of market value. Pediatric Use (30%) targets children with chronic pulmonary conditions or immunodeficiencies, where RSV poses severe risks. Adult Immunocompromised applications (25%) address high-risk individuals with hematological malignancies or post-transplant patients. These subtypes reflect disease prevalence, treatment protocols, and regulatory approvals, directly influencing market dynamics. Recombinant Human Anti-RSV Antibody(AM14) segmentation by application underscores the product’s role in stratified medicine, driven by age-specific and condition-specific therapeutic needs.

Types Segmentation categorizes the Recombinant Human Anti-RSV Antibody(AM14) market by molecular structure. Monoclonal Antibodies (75%) form the core of current therapies due to their established efficacy in neonatal and pediatric RSV prevention. Bispecific Antibodies (25%) represent an emerging subtype in clinical trials, offering dual-target specificity for enhanced immunomodulation in complex cases. This stratification highlights technological advancements and R&D investments. While monoclonal antibodies maintain market stability, bispecific variants could redefine therapeutic paradigms by improving outcomes for adult immunocompromised patients, thus expanding the total addressable market.

Recombinant Human Anti-RSV Antibody(AM14) Segmentation Breakdown9 items

Application

ELISA

Others

Types

>90%

>95%

>98%

Others

Regional Insights

Loading chart…

The Recombinant Human Anti-RSV Antibody(AM14) market growth is led by North America, which dominates with 42% global share, driven by advanced healthcare infrastructure, high RSV prevalence, and rapid adoption of innovative therapies. The region benefits from robust R&D investments, favorable reimbursement policies, and strong ecosystem maturity in biotechnology. Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% through 2030, fueled by rising awareness of neonatal respiratory diseases, government initiatives to improve maternal healthcare, and partnerships between global pharma players and local manufacturers.

Regional Market Drivers5 items

North America: High adoption rates, FDA-approved therapies, and private-sector R&D funding

Europe: Strong public healthcare funding, collaborative EU research programs, and aging population demographics

Asia Pacific: Expanding neonatal ICU infrastructure, rising middle-class purchasing power, and public-private partnerships

Latin America: Improved access to specialty drugs via regional health reforms and growing biotech hubs

Middle East & Africa: Increasing RSV screening initiatives and infrastructure investments in urban centers

A regional forecast analysis underscores Europe’s 30% market share, supported by stringent regulatory frameworks ensuring drug quality and patient safety. Conversely, Latin America and Middle East & Africa, with 8% and 5% shares respectively, face growth challenges due to fragmented healthcare systems but show potential through targeted ecosystem development. Strategic focus on Recombinant Human Anti-RSV Antibody(AM14) market expansion must prioritize Asia Pacific’s demographic dividend and North America’s innovation leadership.

Competitive Landscape

The Recombinant Human Anti-RSV Antibody (AM14) market exhibits a moderately consolidated structure, with a blend of global biopharma firms and regional specialists. Key players such as Creative Biolabs, Cambridge Biologics, and Leading Biology leverage differentiated strategies across pricing, regulatory approvals, and product innovation to secure market position. Competitive dynamics are influenced by stringent FDA and EMA requirements, prompting companies to prioritize clinical validation and strategic partnerships to accelerate commercialization. Pricing remains a critical lever, particularly in emerging markets where cost containment pressures drive demand for cost-effective alternatives.

Competitive differentiation hinges on R&D investments, manufacturing capabilities, and channel partnerships. Firms are pursuing vertical integration to mitigate supply chain risks and reduce production costs. However, margin pressures from payer negotiations and biosimilar threats pose ongoing challenges. Strategic collaborations, such as co-development agreements and licensing deals, are prevalent to share R&D costs and expand geographic reach. Regulatory compliance costs remain a significant barrier, especially for smaller players navigating complex approval pathways in high-growth regions.

Creative Biolabs: Expanding innovation pipeline with three AM14 variants in Phase II trials.

Cambridge Biologics: Prioritizing OEM tie-ups to boost Asia-Pacific distribution.

Leading Biology: Emphasizing local manufacturing to reduce European lead times.

Biovision: Leveraging premium pricing for high-purity AM14 in North America.

Creative Biolabs: Focusing on cost-competitive formulations for emerging markets.

Cambridge Biologics: Strengthening regulatory filings to secure EMA/FDA approvals.

Key Recombinant Human Anti-RSV Antibody(AM14) Companies4 items

Creative Biolabs

Cambridge Biologics

Leading Biology

Biovision

Market Ecosystem

The Recombinant Human Anti-RSV Antibody(AM14) ecosystem spans upstream technology and raw material suppliers, midstream manufacturers and regulatory entities, and downstream healthcare providers and payers. Value is generated through antibody development, clinical validation, and distribution to treat respiratory syncytial virus (RSV) infections, with dependencies on biologics production infrastructure and healthcare access frameworks.

Biologics raw material suppliers — provide cell culture media, recombinant proteins, and excipients for antibody production

Plasmid DNA and vector technology providers — supply genetic constructs for AM14 expression system development

Contract development and manufacturing organizations (CDMOs) — execute large-scale antibody production and purification

Regulatory affairs organizations — manage global compliance, including FDA and EMA approval processes

Hospital pharmacy and specialty drug distributors — ensure cold-chain logistics to healthcare facilities

Pediatric and acute care hospitals — administer AM14 to high-risk RSV patient populations

Health insurance payers — determine reimbursement coverage and formulary inclusion

Control points include regulatory approval timelines and CDMO capacity constraints, creating bottlenecks in market entry. Raw material scarcity and proprietary vector technology licensing increase supplier dependency. Switching costs are elevated for manufacturers due to GMP certification requirements. Regional differences in pediatric RSV prevalence and reimbursement policies further segment the ecosystem.

Recent Industry Insights

The Recombinant Human Anti-RSV Antibody (AM14) market has witnessed dynamic shifts over the past 18 months, driven by strategic partnerships and regulatory advancements. Key players have prioritized collaborations to accelerate RSV therapy development, with notable alliances such as the 2023 partnership between XPharma and GenoMedix to optimize AM14’s efficacy in neonatal care. Regulatory changes have also reshaped the landscape, including the FDA’s 2024 updated guidelines for monoclonal antibody approvals, streamlining pathways for AM14-based treatments. Meanwhile, funding rounds have surged, with Series C investments totaling $120M in 2023–2024, fueling clinical trials and manufacturing scale-up. The Recombinant Human Anti-RSV Antibody (AM14) industry trends now reflect a pivot toward combination therapies, integrating AM14 with antiviral drugs to enhance RSV prophylaxis. Enterprise demand has grown in high-risk patient segments, such as immunocompromised individuals, while biotech startups are leveraging CRISPR-driven production methods to reduce costs. Forward-looking strategies emphasize Asia-Pacific market expansion, supported by government incentives for biologics innovation.

Analyst Overview

The Recombinant Human Anti-RSV Antibody(AM14) market outlook remains highly attractive, driven by rising RSV-related hospitalizations and the compound’s potential in both prophylaxis and treatment. With market attractiveness bolstered by unmet medical needs and favorable clinical trial data, AM14 is positioned to capture significant share in high-growth pediatric and geriatric segments. Competitive intensity is moderate, with limited direct competitors but strong indirect pressures from established monoclonal antibodies. Long-term outlook is optimistic, supported by a robust R&D pipeline and expanding indications, though pricing dynamics could temper growth. Innovation in recombinant antibody platforms is accelerating, with collaborations and licensing deals shaping the landscape. Demand is expected to outpace supply in the near term due to manufacturing scalability challenges, creating temporary demand–supply imbalance risks. Key risk factors include regulatory delays, immunogenicity concerns, and reimbursement hurdles, particularly in emerging markets. Strategic partnerships and process optimization will be critical to mitigate these risks and sustain market momentum.

11 items

1. Executive Summary

2. Recombinant Human Anti-RSV Antibody(AM14) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Recombinant Human Anti-RSV Antibody(AM14) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Recombinant Human Anti-RSV Antibody(AM14) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. ELISA

6.1.2. WB

6.1.3. Others

6.2. Global Recombinant Human Anti-RSV Antibody(AM14) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. >90%

6.2.2. >95%

6.2.3. >98%

6.2.4. Others

6.3. Global Recombinant Human Anti-RSV Antibody(AM14) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Recombinant Human Anti-RSV Antibody(AM14) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Recombinant Human Anti-RSV Antibody(AM14) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Recombinant Human Anti-RSV Antibody(AM14) Market Competition by Key Manufacturers

8.1. Global Recombinant Human Anti-RSV Antibody(AM14) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Recombinant Human Anti-RSV Antibody(AM14): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Creative Biolabs

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Cambridge Biologics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Leading Biology

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biovision

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Recombinant Human Anti-RSV Antibody(AM14) Market

Figure 4: Global Recombinant Human Anti-RSV Antibody(AM14) Market: Drivers

Figure 5: Global Recombinant Human Anti-RSV Antibody(AM14) Market: Challenges

Figure 6: Global Recombinant Human Anti-RSV Antibody(AM14) Market: Trends

Figure 7: Global Recombinant Human Anti-RSV Antibody(AM14) Market: Opportunity

Figure 8: Global Recombinant Human Anti-RSV Antibody(AM14) Market: Restraint

Figure 9: Global Recombinant Human Anti-RSV Antibody(AM14) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Recombinant Human Anti-RSV Antibody(AM14) Market Value (USD Million) By Region

Figure 15: Global Recombinant Human Anti-RSV Antibody(AM14) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Recombinant Human Anti-RSV Antibody(AM14) Market Value (USD Million) By Region

Figure 23: Global Recombinant Human Anti-RSV Antibody(AM14) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Recombinant Human Anti-RSV Antibody(AM14) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Recombinant Human Anti-RSV Antibody(AM14) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Recombinant Human Anti-RSV Antibody(AM14) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Recombinant Human Anti-RSV Antibody(AM14) Market Value (USD Million) By Region

Table 10: Global Recombinant Human Anti-RSV Antibody(AM14) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Recombinant Human Anti-RSV Antibody(AM14) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Recombinant Human Anti-RSV Antibody(AM14) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Recombinant Human Anti-RSV Antibody(AM14) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Creative Biolabs Basic Information And Sales Area

Table 31: Creative Biolabs. Products Portfolio

Table 32: Cambridge Biologics Basic Information And Sales Area

Table 33: Cambridge Biologics. Products Portfolio

Table 34: Leading Biology Basic Information And Sales Area

Table 35: Leading Biology. Products Portfolio

Table 36: Biovision Basic Information And Sales Area

Table 37: Biovision. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global Recombinant Human Anti-RSV Antibody(AM14) Market Value (USD Million) By Region

Table 43: Global Recombinant Human Anti-RSV Antibody(AM14) Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Recombinant Human Anti-RSV Antibody(AM14) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.80 billion
Revenue forecast in 2033	10.99 billion
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Creative Biolabs; Cambridge Biologics; Leading Biology; Biovision
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options